Suppr超能文献

动脉内溶栓的局限性。

Limitations of intra-arterial thrombolysis.

作者信息

Rickard M J, Fisher C M, Soong C V, Hardman D T, Lane R J, Appleberg M

机构信息

Department of Vascular Surgery, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

出版信息

Cardiovasc Surg. 1997 Dec;5(6):634-40. doi: 10.1016/s0967-2109(97)00075-6.

Abstract

The purpose of this study was to assess the efficacy, costs and complications of acutely ischaemic limbs initially treated with urokinase-induced thrombolysis, and to compare the subsequent patencies of occluded native arteries, vein grafts and prosthetic grafts. Data from 45 consecutive episodes of thrombolysis in 37 patients (37 limbs) were reviewed retrospectively. An initial bolus dose of urokinase was used in all limbs, with pulse-spray in nine 30 limbs received additional infusions of urokinase including six who received initial treatment with pulse-spray. Percutaneous transluminal angioplasty or surgical intervention was undertaken at any stage when considered appropriate. There were 14 occluded native arteries (31%), 12 vein grafts (27%), 16 prosthetic polytetrafluoroethylene grafts (35%), and three composite grafts (7%). Thrombolysis was initially successful in 33 episodes (73%). Of these, no additional procedure was required in three, percutaneous transluminal angioplasty in 23, other surgery in 11 and bypass surgery in seven with more than one additional procedure being undertaken in 10. Of the 12 episodes with initial failure, major surgery was performed in eight and no procedure in four. Lysis-related complications occurred in 19 treatment episodes (42%) with major bleeding in seven (16%), minor bleeding in 10 (22%), distal embolization in 11 (24%) and arterial dissection in two (4%). One amputation (2%) and one death (2%), both directly attributable to thrombolysis, occurred within 1 month of treatment. Complications occurred in 10 of 19 (53%) prosthetic or composite grafts, five of 12 (42%) vein grafts, and four of 14 (29%) native artery occlusions (P = 0.38). The median follow-up of patients remaining alive was 24 months. The overall mean (s.e.m.)patency rate at 6 months of lysed vessels or replacement bypass grafts was 44% (8%). Presentation with a native artery and or graft occlusion was associated with superior long-term patency (any subsequent conduit) compared with presentation with an occluded prosthetic graft (log rank chi2[1] = 7.00, P = 0.008) and reflects the inferior run-off of the latter patients. The average cost of thrombolysis in radiological procedures and disposables alone excluding intensive care and complications was AUD$2440.

摘要

本研究旨在评估急性缺血性肢体最初采用尿激酶溶栓治疗的疗效、成本及并发症,并比较闭塞的自体动脉、静脉移植物和人工血管移植物随后的通畅情况。回顾性分析了37例患者(37条肢体)连续45次溶栓治疗的数据。所有肢体均使用了尿激酶初始推注剂量,30条肢体采用脉冲喷射给药,其中9条肢体接受了尿激酶额外输注,包括6例初始采用脉冲喷射治疗的患者。在认为合适的任何阶段均进行了经皮腔内血管成形术或外科干预。共有14条闭塞的自体动脉(31%)、12条静脉移植物(27%)、16条人工聚四氟乙烯血管移植物(35%)和3条复合移植物(7%)。溶栓治疗最初成功33次(73%)。其中,3例无需额外操作,23例行经皮腔内血管成形术,11例行其他手术,7例行旁路手术,10例进行了不止一项额外操作。在最初失败的12次治疗中,8例行大手术,4例未进行任何操作。19次治疗(42%)出现了与溶栓相关的并发症,其中7例(16%)发生大出血,10例(22%)发生小出血,11例(24%)发生远端栓塞,2例(4%)发生动脉夹层。治疗后1个月内发生1例截肢(2%)和1例死亡(2%),均直接归因于溶栓治疗。19条人工或复合移植物中有10条(53%)出现并发症,12条静脉移植物中有5条(42%)出现并发症,14条自体动脉闭塞中有4条(29%)出现并发症(P = 0.38)。存活患者的中位随访时间为24个月。溶栓血管或替代旁路移植物6个月时的总体平均(标准误)通畅率为44%(8%)。与人工血管移植物闭塞患者相比,自体动脉和/或移植物闭塞患者的长期通畅情况更佳(任何后续管道)(对数秩检验χ2[1] = 7.00,P = 0.008),这反映了后一组患者较差的血流灌注情况。仅放射学检查和耗材方面的溶栓平均成本(不包括重症监护和并发症)为2440澳元。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验